Default company panoramic image
Logo

Codagenix, Inc.

A clinical stage, synthetic-biology based platform for constructing live-attenuated vaccine strains the are antigenically identical to the target

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Farmingdale, NY, US
  • Currency USD
  • Founded August 2012
  • Employees 37
  • Incorporation Type C-corp
  • Website codagenix.com

Company Summary

Codagenix utilizes a platform technology termed SAVE to construct live-attenuated viral vaccines. The SAVE customization process uses software-based algorithms to 're-code' the genome of a target virus resulting in a virus that is antigenically identical to the wild-type, virulent strain. Since SAVE-designed vaccine strain are 100% identical animals vaccinated with SAVE-designed vaccines develop a robust and protective immune response.

Team

  • Default avatar
    J. Robert Coleman, PhD, MBA
    COO

    Dr. Coleman, together with Dr. Wimmer and Dr. Mueller co-discovered the SAVE technology and co-founded Codagenix, Inc. His work focuses on rational gene design for vaccine construction. He has multiple high impact publications, is the primary investigator on externally funded research projects, and has project management skills in small business and biotechnology. Dr. Coleman completed his MBA in finance while simultaneously co-founding Codageni

  • Default avatar
    Steffen Mueller, PhD
    CSO

    Dr. Mueller could be considered a preeminent synthetic virologist. Prior to synthetic virology he studied aspects of virus/host interaction, and the cell biology of virus receptors. Together with Dr. Wimmer and Dr. Coleman, Mueller co-developed SAVE, a rational computer-aided approach of designing synthetic, attenuated pathogens. Mueller, Wimmer and Coleman co-founded Codagenix Inc. to develop improved live attenuated human vaccines of medical n

  • Default avatar
    Eckard Wimmer, PhD
    Senior Scientific Advisor

    Dr. Wimmer was recently inducted into the National Academy of Sciences in recognition of his accomplishments as a molecular biologist who has been an expert on viral pathogenesis for over forty years. In the course of these studies Dr. Wimmer has deciphered the genome sequence and genetic structure of poliovirus, the antigenic structure of the poliovirion, and the viral IRESs. Recently, he has co-developed the SAVE platform strategy of whole gen

Advisors

  • Default avatar
    Alan Cohen
    Lawyer
    Unconfirmed
    Default avatar
    Nixon Peabody LLP
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    National Institutes of Health (NIH) - $600,000 (non-dilutive)
    Unconfirmed